DnB Asset Management AS decreased its holdings in Hologic, Inc. (NASDAQ:HOLX) by 52.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,805 shares of the medical equipment provider’s stock after selling 31,200 shares during the period. DnB Asset Management AS’s holdings in Hologic were worth $1,189,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of Hologic by 4.2% in the second quarter. Vanguard Group Inc. now owns 29,547,138 shares of the medical equipment provider’s stock worth $1,340,850,000 after purchasing an additional 1,200,825 shares in the last quarter. Parnassus Investments CA purchased a new position in shares of Hologic in the third quarter worth about $277,062,000. Capital World Investors purchased a new position in shares of Hologic in the second quarter worth about $312,441,000. Victory Capital Management Inc. increased its stake in shares of Hologic by 16.8% in the third quarter. Victory Capital Management Inc. now owns 5,856,778 shares of the medical equipment provider’s stock worth $214,885,000 after purchasing an additional 844,426 shares in the last quarter. Finally, Northern Trust Corp increased its stake in shares of Hologic by 2.5% in the second quarter. Northern Trust Corp now owns 3,277,739 shares of the medical equipment provider’s stock worth $148,743,000 after purchasing an additional 79,697 shares in the last quarter. Hedge funds and other institutional investors own 97.58% of the company’s stock.
Several research firms have recently weighed in on HOLX. Needham & Company LLC reiterated a “buy” rating and issued a $50.00 target price (up previously from $48.00) on shares of Hologic in a research note on Tuesday, January 9th. BidaskClub cut shares of Hologic from a “hold” rating to a “sell” rating in a research note on Saturday. Evercore ISI initiated coverage on shares of Hologic in a research note on Wednesday, January 3rd. They set an “outperform” rating and a $50.00 price objective for the company. Bank of America raised shares of Hologic from a “neutral” rating to a “buy” rating and set a $50.00 price objective for the company in a research note on Thursday, January 4th. Finally, Royal Bank of Canada reaffirmed a “hold” rating and set a $42.00 price objective on shares of Hologic in a research note on Friday, September 22nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $48.79.
Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.01. Hologic had a net margin of 24.70% and a return on equity of 21.69%. The business had revenue of $802.90 million during the quarter, compared to analyst estimates of $792.54 million. During the same period in the previous year, the business posted $0.52 earnings per share. Hologic’s revenue for the quarter was up 10.5% on a year-over-year basis. equities research analysts anticipate that Hologic, Inc. will post 2.15 EPS for the current year.
In other news, VP Karleen Marie Oberton sold 1,256 shares of the business’s stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $39.29, for a total value of $49,348.24. Following the completion of the sale, the vice president now directly owns 9,406 shares in the company, valued at approximately $369,561.74. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Elaine Ullian sold 9,282 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $40.50, for a total transaction of $375,921.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 12,099 shares of company stock valued at $487,223. 0.79% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by BBNS and is the property of of BBNS. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://baseballnewssource.com/markets/dnb-asset-management-as-sells-31200-shares-of-hologic-inc-holx/1838667.html.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with our FREE daily email newsletter.